171 related articles for article (PubMed ID: 9498753)
1. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function.
Kalled SL; Cutler AH; Datta SK; Thomas DW
J Immunol; 1998 Mar; 160(5):2158-65. PubMed ID: 9498753
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
Early GS; Zhao W; Burns CM
J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
[TBL] [Abstract][Full Text] [Related]
3. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis.
Mohan C; Shi Y; Laman JD; Datta SK
J Immunol; 1995 Feb; 154(3):1470-80. PubMed ID: 7529804
[TBL] [Abstract][Full Text] [Related]
4. The NZB X SWR model of lupus nephritis. II. Autoantibodies deposited in renal lesions show a distinctive and restricted idiotypic diversity.
Gavalchin J; Datta SK
J Immunol; 1987 Jan; 138(1):138-48. PubMed ID: 3491155
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD40L accelerates renal disease and adenopathy in MRL-lpr mice in parallel with decreased thymocyte apoptosis.
Russell JQ; Mooney T; Cohen PL; MacPherson B; Noelle RJ; Budd RC
J Immunol; 1998 Jul; 161(2):729-39. PubMed ID: 9670949
[TBL] [Abstract][Full Text] [Related]
6. Lupus prone (SWR x NZB)F1 mice produce potentially nephritogenic autoantibodies inherited from the normal SWR parent.
Gavalchin J; Nicklas JA; Eastcott JW; Madaio MP; Stollar BD; Schwartz RS; Datta SK
J Immunol; 1985 Feb; 134(2):885-94. PubMed ID: 3871219
[TBL] [Abstract][Full Text] [Related]
7. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis.
Quezada SA; Eckert M; Adeyi OA; Schned AR; Noelle RJ; Burns CM
Arthritis Rheum; 2003 Sep; 48(9):2541-54. PubMed ID: 13130474
[TBL] [Abstract][Full Text] [Related]
8. CD40L is necessary for the priming of effector cells for lymphocytic and granulomatous experimental autoimmune thyroiditis.
Peterson KE; Braley-Mullen H
J Autoimmun; 1999 Feb; 12(1):1-12. PubMed ID: 10028017
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses.
Ma J; Xu J; Madaio MP; Peng Q; Zhang J; Grewal IS; Flavell RA; Craft J
J Immunol; 1996 Jul; 157(1):417-26. PubMed ID: 8683147
[TBL] [Abstract][Full Text] [Related]
10. Anti-T cell receptor antibody treatment of mice with lupus-like graft versus host disease: suppression of glomerulonephritis without reduction in anti-DNA antibody levels.
Maeda T; Nomoto K
J Rheumatol; 1995 Dec; 22(12):2259-65. PubMed ID: 8835559
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of pathogenic IgG autoantibody production in CD40L gene-deleted lupus-prone New Zealand Black mice.
Pau E; Chang NH; Loh C; Lajoie G; Wither JE
Clin Immunol; 2011 May; 139(2):215-27. PubMed ID: 21414847
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of auto anti-idiotypic antibodies reactive with antibodies expressing the pathogenic idiotype, IdLNF1, in the (NZB x SWR)F1 model for lupus nephritis and its parental strains.
Uner AH; Tatum AH; Knupp CJ; Gavalchin J
J Autoimmun; 1998 Jun; 11(3):233-40. PubMed ID: 9693971
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS.
Green KA; Noelle RJ; Green WR
Virology; 1998 Feb; 241(2):260-8. PubMed ID: 9499800
[TBL] [Abstract][Full Text] [Related]
14. Reduction of atherosclerosis in mice by inhibition of CD40 signalling.
Mach F; Schönbeck U; Sukhova GK; Atkinson E; Libby P
Nature; 1998 Jul; 394(6689):200-3. PubMed ID: 9671306
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand.
Nakajima A; Hirai H; Kayagaki N; Yoshino S; Hirose S; Yagita H; Okumura K
J Autoimmun; 2000 Mar; 14(2):151-7. PubMed ID: 10677246
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells.
Kaliyaperumal A; Michaels MA; Datta SK
J Immunol; 1999 May; 162(10):5775-83. PubMed ID: 10229810
[TBL] [Abstract][Full Text] [Related]
17. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney.
Zhang JL; Sun DJ; Hou CM; Wei YL; Li XY; Yu ZY; Feng JN; Shen BF; Li Y; Xiao H
Transpl Immunol; 2010 Oct; 24(1):17-25. PubMed ID: 20850528
[TBL] [Abstract][Full Text] [Related]
18. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis.
Kalaaji M; Sturfelt G; Mjelle JE; Nossent H; Rekvig OP
Arthritis Rheum; 2006 Mar; 54(3):914-26. PubMed ID: 16508974
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.
Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
Nephrol Dial Transplant; 2008 Sep; 23(9):2768-76. PubMed ID: 18445640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
